Although inflammasome downstream effectors including anakinra (IL-1 receptor antagonist), canakinumab (IL-1β neutralizing antibody), and rilonacept (soluble decoy receptor for IL-1β and IL-1α) have been approved as therapeutic agents [56], there have been no reports of their use in clinical trials of neurodegenerative diseases including AD and PD. Here, IL1B is linked to Parkinson disease.